Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.

A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.

A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.

The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.

Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.

On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.

Psychotherapy addresses fear and anxiety that can blunt hormone and pelvic floor therapy in menopause care, according to Sheryl Kingsberg, PhD.

SUID was the largest single contributor to the Black-White infant mortality gap in 2024 and drove the biggest share of its rise since 2020.